← Eichor
Study identifier: NCT07034391 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Study Evaluating the Efficacy of PD-1 Inhibitor Combined With Denosumab and Chemotherapy in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Patients With Driver Gene-Negative Status

Condition: Non-Small Cell Lung Cancer  ·  Sponsor: China Medical University, China

PhasePhase 2
Planned participants40
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

This is an interventional study to explore the efficacy and safety of denosumab combined chemotherapy and anti-PD-1/PD-L1 inhibitor in locally advanced or metastatic NSCLC.

This description comes directly from the study's public registry record.

Talk to the study team

Zhang Chief Physician  ·  15909881516  ·  zhangly1105@126.com

Always discuss trial participation with your own doctor first.

Locations (1)

The First Affiliated Hospital of China Medical UniversityShenyang, Liaoning, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07034391